Raia DrogasilBSP:RADL3 -2.04%91 Current Ratio is 1.47 as of Mar. 2026, which is at its 10-year median of 1.47. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.96 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Raia Drogasil ranks worse than 50.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Raia Drogasil's current ratio for the quarter that ended in Mar. 2026 was 1.47.
Raia Drogasil has a current ratio of 1.47. It generally indicates good short-term financial strength.
The historical rank and industry rank for Raia Drogasil's Current Ratio or its related term are showing as below:
BSP:RADL3'
s Current Ratio Range Over the Past 10 Years
Min: 1.31 Med: 1.47 Max: 1.69
Current: 1.47
During the past 13 years, Raia Drogasil's highest Current Ratio was 1.69. The lowest was 1.31. And the median was 1.47.
BSP:RADL3's Current Ratio is ranked worse than 50.07% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs BSP:RADL3: 1.47
Raia Drogasil (BSP:RADL3) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Raia Drogasil Current Ratio Related Terms
Raia Drogasil Current Ratio Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's Current Ratio distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a Current Ratio of 1.47 as of Mar. 2026. This is near median its historical median of 1.47. Over the past decade, Raia Drogasil's Current Ratio has ranged from 1.31 to 1.69. According to the industry distribution chart, Raia Drogasil ranks #341 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 50.1%.
Is Raia Drogasil's Current Ratio too high?
Raia Drogasil's current Current Ratio of 1.47 is near median its 10-year median of 1.47. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 1.69. The Healthcare Providers & Services industry median Current Ratio is 1.47. Raia Drogasil's value of 1.47 is 0% at this industry median. Based on the distribution chart, Raia Drogasil ranks #341 out of 681 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's Current Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #341 out of 681 companies for Current Ratio. This places Raia Drogasil in the lower half of its industry. The industry median Current Ratio is 1.47. Raia Drogasil's value of 1.47 is 0% at this benchmark. Historically, Raia Drogasil's own Current Ratio has ranged from 1.31 to 1.69 over the past decade. While the company's 10-year median is 1.47 vs. the industry median of 1.47, Raia Drogasil has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current Current Ratio of 1.47 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current Current Ratio is 1.47, which is near median its own 10-year median of 1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.96, compared to a current price of R$16.81 — trading 43.9% below its estimated fair value. The current Current Ratio is 1.47, which is near median its 10-year median of 1.47 and 0% at the Healthcare Providers & Services industry median of 1.47. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current Current Ratio is 1.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$16.81 is trading 43.9% below its estimated GF Value™ of R$29.96.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
Current Ratio: 1.47 (near median its 10-year median of 1.47)
GF Value™: R$29.96 vs. price of R$16.81 (43.9% below fair value)
Industry Position: 0% at the Healthcare Providers & Services median (#341 of 681)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
